- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:06 | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion | 52 | GlobeNewswire (Europe) | Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla.... ► Artikel lesen | |
| Di | Cadrenal: Positive Signale bei Thrombose-Studie trotz verfehltem Primärziel | - | Investing.com Deutsch | ||
| Di | Cadrenal's CAD-1005 shows reduction in blood clots in HIT trial | 1 | Investing.com | ||
| Di | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement | 440 | GlobeNewswire (Europe) | Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase... ► Artikel lesen | |
| Di | Cadrenal Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| CADRENAL THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.01. | Cadrenal: 12-LOX-Inhibitor zeigt Potenzial bei seltener Blutgerinnungsstörung | - | Investing.com Deutsch | ||
| 12.01. | Cadrenal highlights potential of 12-LOX inhibitor for blood disorder | 1 | Investing.com | ||
| 30.12.25 | Cadrenal Therapeutics: Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System | 359 | ACCESS Newswire | PONTE VEDRA, FL / ACCESS Newswire / December 30, 2025 / Some companies enter a market because they see opportunity. Others step in because the situation has become unsustainable, and someone has to... ► Artikel lesen | |
| 29.12.25 | Cadrenal Therapeutics: Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On | 285 | ACCESS Newswire | PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods. For years, the field centered itself... ► Artikel lesen | |
| 24.12.25 | Cadrenal Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 23.12.25 | Cadrenal Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.12.25 | Cadrenal Therapeutics: Cadrenal's Quiet Expansion Play Is Starting to Get Loud | 561 | ACCESS Newswire | PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the year with a calm, almost surgical approach to building out its foundation. While... ► Artikel lesen | |
| 12.12.25 | Cadrenal Therapeutics: Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market | 552 | ACCESS Newswire | PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread by the market. Yes, the Company is intentionally narrowly focused. However... ► Artikel lesen | |
| 11.12.25 | Cadrenal Therapeutics acquires first-in-class HIT treatment from Veralox | 1 | Investing.com | ||
| 11.12.25 | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) | 199 | GlobeNewswire (Europe) | Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing... ► Artikel lesen | |
| 11.12.25 | Cadrenal Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.12.25 | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 01.12.25 | Cadrenal Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.11.25 | Cadrenal Therapeutics Inc.: Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award | 1 | GlobeNewswire (USA) | ||
| 18.11.25 | Cadrenal Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,25 | -0,05 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| EVOTEC | 5,686 | -2,94 % | Evotec Aktie: Kann man "diesem Braten wirklich trauen"? | © Foto: Julia Koblitz auf Unsplash (Symbolbild)Neue Aufträge, ein Sparprogramm und frische Analystenkommentare. Die Evotec-Aktie sendet wieder Lebenszeichen. Doch wer die Geschichte dieses Hamburger... ► Artikel lesen | |
| BB BIOTECH | 52,10 | +1,36 % | BB Biotech: Von Innovation zu Wertrealisierung - Der Biotech-Markt in einer neuen Phase | Nach mehreren Jahren, die von erhöhten Kapitalkosten, Bewertungsdruck und ausgeprägter Risikoaversion geprägt waren, hat sich das Umfeld seit dem vergangenen Jahr spürbar stabilisiert. Finanzierungsbedingungen... ► Artikel lesen | |
| AMGEN | 330,20 | +0,50 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,691 | +1,32 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 159,35 | -1,85 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,920 | +0,84 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,750 | +0,33 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 13,000 | +11,49 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM | CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 44,600 | -1,33 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,322 | -1,19 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,415 | -2,35 % | NurExone Biologic: Pionier in der Exosomen-Medizin! | ||
| BIOMARIN PHARMACEUTICAL | 51,62 | -1,19 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,035 | -1,02 % | Sarepta Therapeutics, Inc. - 10-K, Annual Report | ||
| EXELIXIS | 34,820 | -6,65 % | 3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade |
CADRENAL THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,630 (+7,71 %) liegt der Kurs bei 8,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CADRENAL THERAPEUTICS INC finden Sie auf Wallstreet Online.